Progerinin not checked
PRG Science & Technology Co., Ltd. · SLC-D011
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. . There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase.”In the company’s words, NCT05847179 on ClinicalTrials.gov
- Tested for
- Werner Syndrome
- Main trialPhase 2
- “This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.”In the company’s words, NCT05847179 on ClinicalTrials.gov
- Other names
- SLC-D011
Other drugs for Werner Syndrome
- NDI-219216Nimbus Wadjet, Inc. · Phase 1/2
Coming up1
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2027 | Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome | |
| Phase 2Completed | 30 Mar 2026 | Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) | |
| Phase 1Completed | 27 Jul 2021 | Phase I Study of Progerinin in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026